Anthony Comuzzie, The Obesity Society CEO
November 1, 2024 07:00 AM EDT
Pharma

Q&A with Obe­si­ty So­ci­ety’s CEO as the field pre­pares for next-gen meds

Kyle LaHucik

Senior Reporter

The race to cre­ate the next best med­ica­tion for obe­si­ty is well un­der­way, and the in­cum­bents are do­ing every­thing they can to shore up man­u­fac­tur­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

Fol­low­ing 2019 re­jec­tion, FDA ad­comm votes against Lex­i­con's type 1 di­a­betes and CKD drug

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

A service from the Financial Times